Regeneron's Dupixent Machine Hits $17.8B as EYLEA Franchise Fights Biosimilar Tide and 23andMe Bet Reshapes Genetic Drug Discovery

Regeneron closed FY2025 with $14.3B in revenue, powered by Dupixent's 26% global sales growth to $17.8B, while the legacy EYLEA franchise battles Vabysmo and incoming biosimilars. The $256M acquisition of 23andMe's 15M-person genetic database — layered atop the Regeneron Genetics Center's 2.7M sequenced exomes — is the boldest data play in biopharma.

REGN · Health Care · February 16, 2026

S&P 500 Position

Regeneron is one of the largest pure-play biotechs in the S&P 500, sitting alongside Vertex Pharmaceuticals (VRTX), Amgen (AMGN), and Gilead Sciences (GILD) in the Health Care sector's biotechnology sub-industry. Within the broader S&P 500 Health Care sector (~12% of the index), Regeneron competes for weight against mega-cap pharma names like Eli Lilly, Johnson & Johnson, UnitedHealth, and AbbVie. Its $85B market cap places it firmly in large-cap territory but well below the $200B+ pharma giants. The competitive dynamic is increasingly shaped by Roche (via Vabysmo in ophthalmology), Sanofi (as both partner and potential future competitor when Dupixent collaboration terms evolve), and emerging biosimilar manufacturers targeting EYLEA.

Index Weight: ~0.17% | Rank: Approximately #90-110 in the S&P 500 by market cap

Company Overview

Regeneron is navigating a franchise transition in real time. Dupixent — the IL-4/IL-13 blocker co-commercialized with Sanofi — is now the most widely used innovative branded antibody medicine globally, with over 1.4 million active patients and indications spanning atopic dermatitis, asthma, COPD, CRSwNP, eosinophilic esophagitis, bullous pemphigoid, and chronic spontaneous urticaria. It generated $17.8B in global net sales in 2025, up 26% year-over-year, and is still gaining approvals (allergic fungal rhinosinusitis is under FDA priority review with a February 2026 target date). Meanwhile, the EYLEA franchise — once Regeneron's crown jewel in ophthalmology — is declining under competitive pressure from Roche's dual-mechanism Vabysmo and looming U.S. biosimilar entry expected by mid-2026. EYLEA HD (the 8mg high-dose reformulation) is the transition vehicle: it grew 36% to $1.6B in U.S. sales for FY2025, with new FDA approvals for RVO and monthly dosing flexibility, but combined EYLEA HD + EYLEA U.S. sales still dropped 27% year-over-year. The more interesting strategic play is what's happening beneath the commercial layer. Regeneron's acquisition of 23andMe out of bankruptcy for $256M gives it access to genetic data from 15 million consented individuals, which merges with the Regeneron Genetics Center's existing database of 2.7 million sequenced exomes linked to electronic health records. This is the largest proprietary human genetics dataset in biopharma, and Regeneron is using it to fuel target identification, biomarker discovery, and clinical trial optimization through machine learning. The company also has approximately 45 product candidates in clinical development — including linvoseltamab (bispecific BCMAxCD3 for multiple myeloma, now FDA-approved), odronextamab (CD20xCD3 bispecific for lymphoma), fianlimab (LAG-3 inhibitor in oncology), garetosmab (anti-activin A for FOP), and DB-OTO (gene therapy for congenital hearing loss). Regeneron plans to invest $9B+ in domestic manufacturing and R&D, including a new $2B bulk manufacturing facility in Saratoga Springs, New York.

Products & Revenue

Regeneron's revenue model is split between collaboration revenue (primarily its profit-sharing arrangement with Sanofi on Dupixent and Kevzara, plus a collaboration with Bayer on EYLEA outside the U.S.), direct U.S. net product sales (EYLEA HD, EYLEA, Libtayo, and other products), and other revenue (royalties on Ilaris from Novartis, ARCALYST profits, and contract manufacturing). Sanofi collaboration revenue was by far the largest contributor in FY2025 at $5.88B, driven by Dupixent's global dominance. Direct product sales are anchored by the EYLEA franchise and the fast-growing Libtayo oncology franchise.

Sanofi Collaboration Revenue (Dupixent/Kevzara) (~41%): Regeneron's share of profits from Sanofi's commercialization of Dupixent and Kevzara. Dupixent global net sales hit $17.8B in FY2025 (+26% YoY). Regeneron's collaboration profit share grew 30% to $5.88B.

EYLEA HD U.S. Net Product Sales (~11%): The 8mg high-dose aflibercept formulation for retinal diseases (wAMD, DME, DR, RVO). Grew 36% to $1.6B in FY2025 as patients transition from legacy EYLEA. FDA approved monthly dosing and RVO indication in late 2025.

EYLEA (2mg) U.S. Net Product Sales (~19%): Legacy 2mg aflibercept injection in decline. Combined EYLEA + EYLEA HD U.S. sales dropped 27% in Q4 2025 due to Vabysmo competition, compounded bevacizumab use, and ongoing transition to EYLEA HD.

Libtayo Global Net Product Sales (~10%): PD-1 checkpoint inhibitor (cemiplimab) for CSCC, BCC, and NSCLC. Generated ~$1.4B in FY2025 sales, growing ~20%+ YoY. Recently approved as first immunotherapy for high-risk adjuvant CSCC.

Bayer Collaboration Revenue (~12%): Revenue from collaboration with Bayer on EYLEA/EYLEA HD outside the U.S. Bayer records international sales; Regeneron receives a share of profits.

Other Revenue (Ilaris Royalties, ARCALYST, Other) (~7%): Royalties on Novartis's Ilaris (which surpassed $1.5B in sales in 2025, hitting the top 15% royalty tier), ARCALYST profit share, contract manufacturing income, and smaller product sales (Praluent, Kevzara, Evkeeza, etc.).

Based on Regeneron FY2025 10-K filing and Q4 2025 earnings release (January 30, 2026). Revenue percentages are approximate, derived from disclosed segment data.

Leadership

Leonard S. Schleifer, M.D., Ph.D.

CEO since 1988. Co-founded Regeneron in 1988 and has served as President and CEO since inception — a 37-year tenure that's extraordinary in biotech. Board-certified neurologist with an M.D. and Ph.D. in Pharmacology from the University of Virginia. Under his leadership, Regeneron has grown from a neurotrophic factors startup to one of the world's most valuable biotech companies, with 13 approved or authorized treatments and a pipeline of 45 clinical-stage candidates.

George D. Yancopoulos, M.D., Ph.D., Co-Founder, Board co-Chair, President and Chief Scientific Officer: The scientific architect of Regeneron. Was the 11th most highly cited scientist globally in the 1990s. Principal inventor of VelocImmune, TRAP technology, and most of the company's foundational platforms. Elected to the National Academy of Sciences in 2004. Drives the genetics-first drug discovery strategy that produced Dupixent, EYLEA, Libtayo, and Inmazeb.

Andrew J. Murphy, Ph.D., Co-Chief Scientific Officer, Executive Vice President of Research: Joined Regeneron in 1999. Co-inventor of VelociGene and VelocImmune — the two technologies that underpin virtually every antibody candidate the company has produced. Leads multiple technology centers and therapeutic focus areas. Ph.D. in Human Genetics from Columbia.

Aris Baras, M.D., Senior Vice President, Head of the Regeneron Genetics Center: Leads the RGC, which has sequenced 2.7M+ exomes and identified 30+ novel genetic targets. Now overseeing integration of 23andMe's 15M-person genetic dataset. The RGC is the engine behind Regeneron's genetics-driven target discovery strategy.

Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer: Promoted to CFO in January 2025 after serving as SVP and Controller since 2021. A Regeneron lifer who joined in 2012. Overseeing the company's first-ever quarterly dividend program and $4.5B share repurchase authorization.

Marion McCourt, Executive Vice President, Commercial: Leads commercial operations globally, managing the Dupixent/EYLEA franchise transitions and Libtayo's rapid expansion into new oncology indications. Key figure in navigating the biosimilar competitive landscape.

The AI Angle

Genetics-first AI fueling the largest proprietary human genome database in biopharma

Regeneron's AI strategy is inseparable from its genetics infrastructure. The Regeneron Genetics Center (RGC), launched in 2013, has sequenced over 2.7 million exomes and linked them to de-identified electronic health records from collaborators worldwide. The center uses machine learning to perform large-scale analyses that identify statistical associations between genetic variants and disease phenotypes — a process that has already uncovered 30+ novel drug targets, including ANGPTL3 (which became Evkeeza for homozygous familial hypercholesterolemia) and targets for obesity, liver disease, and BRCA-associated cancers. The $256M acquisition of 23andMe in 2025 dramatically expands this dataset with genetic information from 15 million consented individuals, creating what is likely the largest proprietary human genetics database in the pharmaceutical industry. Regeneron plans to integrate 23andMe's data into its RGC workflows for target identification, biomarker discovery, and clinical trial optimization. On the infrastructure side, Regeneron runs a multicloud stack anchored on AWS, with Microsoft Azure for business applications and Google Cloud Platform for specialized scientific computation. The company built its own data lakehouses on AWS through a platform called Regeneron Deva Platform (which won a 2020 CIO 100 Award), managing approximately 200TB of interconnected data spanning its genetics center, manufacturing, clinical safety, and early research operations. Data pipelines use Airflow, NiFi, and Kafka; warehousing runs on Redshift; and data science work leverages Databricks, Dataiku, Python, and Jupyter Notebooks. The infrastructure is designed to connect 30 years of heterogeneous research data into a unified analytics layer. AI also plays a role in Regeneron's antibody discovery workflow. The VelocImmune platform generates fully human antibodies from genetically humanized mice, and computational algorithms help optimize antibody properties in silico — predicting binding affinities, stability, and developability before candidates enter wet-lab validation. In 2025, Regeneron is applying AI to multi-omic data analysis, combining DNA, RNA, and proteomic information to guide research in autoimmune and neurological diseases. The company's Chief Data Officer at the RGC, Jeffrey Reid, has been publicly exploring how emerging AI/ML tools can accelerate discovery while maintaining equitable and ethical outputs. The competitive risk is real: companies like Recursion, Isomorphic Labs (DeepMind), and Insilico Medicine are building AI-native drug discovery platforms. But Regeneron's edge is its proprietary data moat — the combination of RGC's sequenced exomes, 23andMe's consumer genomics, clinical trial datasets, and 30+ years of wet-lab validation creates a feedback loop that pure-play AI companies cannot replicate. The question is execution speed: can Regeneron's in-house AI capabilities keep pace with the rapid advances in foundation models for biology, or will it need to partner more aggressively with AI-native firms?

Financial Snapshot

Revenue (TTM): $14.3B — TTM (ending December 31, 2025) | Net Income: $4.5B net income

Margins: Gross ~79-80% on net product sales (per 2026 guidance), net 31.4%

Regeneron's balance sheet is a fortress: minimal debt, substantial cash reserves (~$17.6B in cash and marketable securities), and strong free cash flow generation. The company initiated its first-ever quarterly dividend in early 2025 and expanded share repurchase capacity to ~$4.5B, signaling confidence in sustained cash generation. Capital allocation is shifting toward aggressive manufacturing investment — over $9B committed to domestic facilities including a new $2B plant in Saratoga Springs — while R&D spend is guided at $6.45-6.68B for 2026, reflecting the advancement of its late-stage pipeline. Revenue growth decelerated to 1% in FY2025 as EYLEA declines partially offset Dupixent and Libtayo gains, but the trajectory should inflect as collaboration margins improve and new products launch.

1-Year Performance

$803.17 as of February 16, 2026. The stock has recovered sharply from its 52-week low of $476.49, now trading within 2% of its 52-week high of $821.11.

REGN experienced a dramatic V-shaped recovery over the past year, plunging to $476 in mid-2025 on fears of accelerating EYLEA erosion, an FDA Complete Response Letter for the EYLEA HD pre-filled syringe, and biosimilar anxiety. The stock rallied 68% from that trough on a string of positive catalysts: FDA approvals for EYLEA HD in RVO and monthly dosing, Libtayo's adjuvant CSCC approval, Dupixent's record sales trajectory, and the resolution of manufacturing filler issues. Analyst consensus remains 'Buy' with targets ranging from $730 to $1,057, though the mean target of ~$798 is now slightly below the current price, suggesting the easy money in the recovery trade has been made.

Recent News

Fun Fact: Every FDA-approved antibody therapy Regeneron has produced — Dupixent, EYLEA, Libtayo, Praluent, Kevzara, Evkeeza, Inmazeb, and more — was generated using VelocImmune mice, which carry the full repertoire of human immunoglobulin variable genes spliced into endogenous mouse constant regions. When these mice were first engineered, they represented the largest-scale precision genetic engineering feat ever achieved — replacing six megabases of mouse DNA with human DNA. Co-founder George Yancopoulos first conceived the idea of creating such a genetically humanized mouse as a graduate student at Columbia, decades before the technology existed to build it. The VelocImmune platform has generated more approved antibody therapeutics than any other single discovery platform in the history of biotechnology.